Sponsor pipeline

Merck (MSD) clinical trial pipeline

Get alerts when Merck (MSD)'s trials change

233 active trials 113 recruiting 107 Phase 3 45 disease areas 133 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-02

What changed in the last 30 days showing 40 of 133 changes on 20 trials

2026-09-29
Reclassified as terminated (was completed)
Trial terminated: The study stopped due to futility
NCT03833167 Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants… · Phase 3
2026-09-29
Reclassified as terminated (was completed)
Trial terminated: The study stopped due to futility
NCT04191096 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen… · Phase 3
2026-09-29
Reclassified as terminated (was completed)
Trial terminated: The study stopped due to futility
NCT03834493 Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in… · Phase 3
2026-09-18
Reclassified as terminated (was completed)
Trial terminated: Business Reasons
NCT04738487 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475)… · Phase 3
2026-09-12
Reclassified as terminated (was completed)
Trial terminated: MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was...
NCT05226598 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With… · Phase 3
2026-09-04
Reclassified as terminated (was completed)
Trial terminated: Business Reasons
Results posted: 2026-09-03
NCT04246177 Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in… · Phase 3
2026-09-15
Reclassified as terminated (was completed)
Trial terminated: Business Reasons
NCT04191135 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After… · Phase 2
2026-09-15
Withdrawn before enrolling
Trial withdrawn: Business Reasons
NCT07224477 A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2
2026-09-24
Primary completion pushed: 2034-01-14 → 2034-04-22
Completion pushed: 2034-01-14 → 2034-04-22
NCT07405164 Extension Study for Participants in Studies That Include Belzutifan… · Phase 3
2026-09-23
Primary completion pushed: 2029-12-27 → 2032-11-18
Completion pushed: 2029-12-27 → 2032-11-18
NCT04924075 Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL)… · Phase 2
2026-09-03
Primary completion pushed: 2026-12-31 → 2027-12-31
Completion pushed: 2027-01-29 → 2028-01-29
NCT06049212 Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in… · Phase 1
2026-09-24
Primary endpoint(s) modified
NCT06312176 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With… · Phase 3
2026-09-18
Primary endpoint(s) modified
NCT06136650 A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA)… · Phase 3
2026-09-18
Primary endpoint(s) modified
Interventions modified
Trial sites expanded: 181 → 362 locations
NCT07159763 A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza… · Phase 3
2026-09-11
Primary endpoint(s) modified
NCT04624204 Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab… · Phase 3
2026-09-03
Primary endpoint(s) modified
Enrollment increased: 460 → 605 participants
Interventions modified
Completion pushed: 2029-03-27 → 2031-02-07
Trial arms changed: 10 → 14
NCT06843447 A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) · Phase 1/2
2026-10-01
Enrollment closed, study ongoing
Primary completion pushed: 2026-12 → 2027-03-01
Completion moved earlier: 2027-06 → 2027-03-01
NCT05270525 Effect of Ensifentrine on Sputum Markers of Inflammation in COPD · Phase 2
2026-09-29
Recruitment opened
NCT07705607 A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular… · Phase 3
2026-09-29
Recruitment opened
NCT07722611 A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025) · Phase 2/3
2026-09-29
Enrollment closed, study ongoing
NCT06788912 Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung… · Phase 2

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-09-30 NCT07850310 A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis… Phase 1 Not Yet Recruiting
2026-09-30 NCT07850609 A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse… Phase 2 Not Yet Recruiting
2026-09-24 NCT07839585 A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and… Phase 3 Not Yet Recruiting
2026-09-21 NCT07829783 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab… Phase 3 Not Yet Recruiting
2026-09-16 NCT07821944 A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India… Phase 3 Not Yet Recruiting
2026-09-03 NCT07801027 A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From… Phase 4 Not Yet Recruiting

Active trials by phase

Phase 1
34
Phase 1/2
34
Phase 2
54
Phase 2/3
7
Phase 3
100
Phase 4
2
Not charted: 2 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 233

NCT IDTitleConditionStatusUpdated
Phase 4
NCT07801027 A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From… Neoplasm Malignant Not Yet Recruiting 2026-09-03
NCT07600723 A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in… Pulmonary Arterial Hypertension Not Yet Recruiting 2026-08-07
Phase 3
NCT06997497 A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… Colon Adenocarcinoma Recruiting 2026-10-01
NCT07190248 A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With… Non-small Cell Lung Cancer Recruiting 2026-10-01
NCT07218029 A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension… Pulmonary Arterial Hypertension Recruiting 2026-10-01
NCT07431827 MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC… Non-small Cell Lung Cancer Recruiting 2026-10-01
NCT07513376 A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated… Non-small Cell Lung Cancer Recruiting 2026-10-01
NCT07554339 A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell… Non-small Cell Lung Cancer Recruiting 2026-10-01
NCT07705555 A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular… Diabetic Retinopathy Recruiting 2026-10-01
NCT07705607 A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular… Diabetic Retinopathy Recruiting 2026-10-01
NCT06430801 A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants… Crohn's Disease Recruiting 2026-09-29
NCT06623422 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in… Carcinoma, Non-Small-Cell Lung Recruiting 2026-09-28
NCT07060807 A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) Breast Neoplasms Recruiting 2026-09-28
NCT06136650 A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA)… Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting 2026-09-25
NCT06170788 Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab… Non-small Cell Lung Cancer (NSCLC) Recruiting 2026-09-25
NCT06312137 A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab… Non Small Cell Lung Cancer Recruiting 2026-09-25
NCT06312176 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With… Breast Neoplasms Recruiting 2026-09-25
NCT06393374 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not… Triple-Negative Breast Cancer Recruiting 2026-09-25
NCT06717347 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus… Diffuse Large B-Cell Lymphoma Recruiting 2026-09-25
NCT06841354 A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination… Triple Negative Breast Neoplasms Recruiting 2026-09-25
NCT06966700 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast… Breast Neoplasms Recruiting 2026-09-25
NCT07216703 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… Cervical Cancer Recruiting 2026-09-25
NCT07419295 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer… Bladder Cancer Recruiting 2026-09-25
NCT07489495 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… Carcinoma, Renal Cell Recruiting 2026-09-25
NCT05947851 A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line… Leukemia, Lymphocytic, Chronic, B-Cell Recruiting 2026-09-24
See all 233 active Merck (MSD) trials with filters →

Disease areas by active trials, top 10 of 45

Lung Cancer (36) · Non-Small Cell Lung Cancer (NSCLC) (26) · Kidney Cancer (16) · Bladder Cancer (14) · Breast Cancer (10) · Hypertension (8) · Leukemia (8) · Non-Hodgkin Lymphoma (8) · DLBCL (7) · Small Cell Lung Cancer (7)

Get alerts when Merck (MSD)'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free